Published in J Chemother on October 01, 2004
Novel approaches to developing new antibiotics for bacterial infections. Br J Pharmacol (2007) 2.43
Synthesis, characterization, and antimicrobial activity of an ampicillin-conjugated magnetic nanoantibiotic for medical applications. Int J Nanomedicine (2014) 0.79
Local Intramedullary Delivery of Vancomycin Can Prevent the Development of Long Bone Staphylococcus aureus Infection. PLoS One (2016) 0.75
Antibiotic-associated pseudomembranous colitis due to toxin-producing clostridia. N Engl J Med (1978) 14.65
Tularemia as a biological weapon: medical and public health management. JAMA (2001) 13.23
Evidence for a clonal origin of methicillin resistance in Staphylococcus aureus. Science (1993) 10.09
Decreased susceptibility of Streptococcus pneumoniae to fluoroquinolones in Canada. Canadian Bacterial Surveillance Network. N Engl J Med (1999) 10.06
Botulinum toxin as a biological weapon: medical and public health management. JAMA (2001) 9.18
Guidelines for the management of adults with community-acquired pneumonia. Diagnosis, assessment of severity, antimicrobial therapy, and prevention. Am J Respir Crit Care Med (2001) 9.08
Susceptibility of anaerobes to cefoxitin and other cephalosporins. Antimicrob Agents Chemother (1975) 8.86
Plague as a biological weapon: medical and public health management. Working Group on Civilian Biodefense. JAMA (2000) 8.45
Invasive group A streptococcal infections in Ontario, Canada. Ontario Group A Streptococcal Study Group. N Engl J Med (1996) 8.41
Anaerobic infections. 1. N Engl J Med (1974) 8.02
Smallpox as a biological weapon: medical and public health management. Working Group on Civilian Biodefense. JAMA (1999) 7.96
Practice guidelines for the management of community-acquired pneumonia in adults. Infectious Diseases Society of America. Clin Infect Dis (2000) 7.80
Clindamycin-associated colitis due to a toxin-producing species of Clostridium in hamsters. J Infect Dis (1977) 7.68
Correlation of antimicrobial pharmacokinetic parameters with therapeutic efficacy in an animal model. J Infect Dis (1988) 7.50
Emergence of vancomycin-resistant enterococci in New York City. Lancet (1993) 7.37
Anthrax as a biological weapon: medical and public health management. Working Group on Civilian Biodefense. JAMA (1999) 7.06
Nomenclature of major antimicrobial-resistant clones of Streptococcus pneumoniae defined by the pneumococcal molecular epidemiology network. J Clin Microbiol (2001) 6.66
Role of Clostridium difficile in antibiotic-associated pseudomembranous colitis. Gastroenterology (1978) 5.91
Comparison of two toxins produced by Clostridium difficile. Infect Immun (1981) 5.16
Pharmacodynamics of levofloxacin: a new paradigm for early clinical trials. JAMA (1998) 4.99
In vivo activities of amoxicillin and amoxicillin-clavulanate against Streptococcus pneumoniae: application to breakpoint determinations. Antimicrob Agents Chemother (1998) 4.88
Comparative antibiotic dose-effect relations at several dosing intervals in murine pneumonitis and thigh-infection models. J Infect Dis (1989) 4.79
Glanders in a military research microbiologist. N Engl J Med (2001) 4.77
Community-acquired pneumonia in adults: guidelines for management. The Infectious Diseases Society of America. Clin Infect Dis (1998) 4.55
Clostridium difficile colitis: an efficient clinical approach to diagnosis. Ann Intern Med (1995) 4.42
Cytotoxicity assay in antibiotic-associated colitis. J Infect Dis (1979) 4.39
Postantibiotic suppression of bacterial growth. Rev Infect Dis (1981) 4.26
Epidemiology of ciprofloxacin resistance and its relationship to extended-spectrum beta-lactamase production in Klebsiella pneumoniae isolates causing bacteremia. Clin Infect Dis (2000) 4.24
Outcome of cephalosporin treatment for serious infections due to apparently susceptible organisms producing extended-spectrum beta-lactamases: implications for the clinical microbiology laboratory. J Clin Microbiol (2001) 4.19
Voriconazole versus a regimen of amphotericin B followed by fluconazole for candidaemia in non-neutropenic patients: a randomised non-inferiority trial. Lancet (2005) 4.17
Evasion of human innate and acquired immunity by a bacterial homolog of CD11b that inhibits opsonophagocytosis. Nat Med (2001) 4.09
Use of antibiotics. A brief exposition of the problem and some tentative solutions. Ann Intern Med (1973) 4.07
Isolation rates and toxigenic potential of Clostridium difficile isolates from various patient populations. Gastroenterology (1981) 4.04
Clindamycin-induced enterocolitis in hamsters as a model of pseudomembranous colitis in patients. Infect Immun (1978) 3.93
Experimental intra-abdominal abscesses in rats: development of an experimental model. Infect Immun (1974) 3.91
Clinical and laboratory observations in Clostridium difficile colitis. Am J Clin Nutr (1980) 3.89
Quantitative bacteriology of the vaginal flora. J Infect Dis (1977) 3.81
Principles of appropriate antibiotic use for acute pharyngitis in adults: background. Ann Intern Med (2001) 3.75
Immunogenicity and impact on nasopharyngeal carriage of a nonavalent pneumococcal conjugate vaccine. J Infect Dis (1999) 3.72
Guidelines for the initial management of adults with community-acquired pneumonia: diagnosis, assessment of severity, and initial antimicrobial therapy. American Thoracic Society. Medical Section of the American Lung Association. Am Rev Respir Dis (1993) 3.68
Management of anaerobic infections. Ann Intern Med (1975) 3.62
The capsular polysaccharide of Bacteroides fragilis as a virulence factor: comparison of the pathogenic potential of encapsulated and unencapsulated strains. J Infect Dis (1977) 3.62
Methicillin-resistant Staphylococcus aureus in horses and horse personnel, 2000-2002. Emerg Infect Dis (2005) 3.54
A clinical score to reduce unnecessary antibiotic use in patients with sore throat. CMAJ (1998) 3.46
Failure of chloramphenicol therapy in penicillin-resistant pneumococcal meningitis. Lancet (1992) 3.42
Persistent effect of antibiotics on Staphylococcus aureus after exposure for limited periods of time. J Infect Dis (1977) 3.38
Rapid diagnosis of anaerobic infections by direct gas-liquid chromatography of clinical speciments. J Clin Invest (1976) 3.34
The validity of a sore throat score in family practice. CMAJ (2000) 3.34
A controlled trial of early versus late treatment with zidovudine in symptomatic human immunodeficiency virus infection. Results of the Veterans Affairs Cooperative Study. N Engl J Med (1992) 3.34
Use of preclinical data for selection of a phase II/III dose for evernimicin and identification of a preclinical MIC breakpoint. Antimicrob Agents Chemother (2001) 3.33
Tetraspanins. Cell Mol Life Sci (2001) 3.33
Detection of vancomycin resistance in Enterococcus species. J Clin Microbiol (1992) 3.30
Anaerobic pleuropulmonary infections. Medicine (Baltimore) (1972) 3.30
Society for Healthcare Epidemiology of America and Infectious Diseases Society of America Joint Committee on the Prevention of Antimicrobial Resistance: guidelines for the prevention of antimicrobial resistance in hospitals. Clin Infect Dis (1997) 3.29
Microbial synergy in experimental intra-abdominal abscess. Infect Immun (1976) 3.21
Prevalence and characterization of the mechanisms of macrolide, lincosamide, and streptogramin resistance in isolates of Streptococcus pneumoniae. Antimicrob Agents Chemother (1998) 3.19
Anaerobic infections (second of three parts). N Engl J Med (1974) 3.18
Principles of appropriate antibiotic use for acute rhinosinusitis in adults: background. Ann Intern Med (2001) 3.15
Colitis induced by Clostridium difficile. Rev Infect Dis (1980) 3.15
Anaerobic infections (third of three parts). N Engl J Med (1974) 3.13
In vivo postantibiotic effect in a thigh infection in neutropenic mice. J Infect Dis (1988) 3.09
Larger vancomycin doses (at least four grams per day) are associated with an increased incidence of nephrotoxicity. Antimicrob Agents Chemother (2008) 3.09
Management of community-acquired pneumonia in the era of pneumococcal resistance: a report from the Drug-Resistant Streptococcus pneumoniae Therapeutic Working Group. Arch Intern Med (2000) 3.09
Enzyme immunoassays for detection of Clostridium difficile toxins A and B in fecal specimens. J Infect Dis (1984) 3.07
Treatment of anaerobic infections with lincomycin and clindamycin. N Engl J Med (1972) 3.05
Antibiotic-associated pseudomembranous colitis. Rev Infect Dis (1980) 3.02
In vivo pharmacodynamic activity of daptomycin. Antimicrob Agents Chemother (2004) 2.88
Animal model pharmacokinetics and pharmacodynamics: a critical review. Int J Antimicrob Agents (2002) 2.88
Oral vancomycin for antibiotic-associated pseudomembranous colitis. Lancet (1978) 2.87
Cultures for Clostridium difficile in stools containing a cytotoxin neutralized by Clostridium sordellii antitoxin. J Clin Microbiol (1979) 2.86
Daptomycin: a novel agent for Gram-positive infections. Expert Opin Investig Drugs (1999) 2.83
Severely reduced female fertility in CD9-deficient mice. Science (2000) 2.80
Pseudomembranous enterocolitis (antibiotic-related colitis). Adv Intern Med (1977) 2.73
Intravenous immunoglobulin therapy for streptococcal toxic shock syndrome--a comparative observational study. The Canadian Streptococcal Study Group. Clin Infect Dis (1999) 2.69
Nosocomial infection caused by gentamicin-resistant, streptomycin-sensitive Klebsiella. J Infect Dis (1975) 2.66
In vivo pharmacodynamics of a new oxazolidinone (linezolid). Antimicrob Agents Chemother (2002) 2.66
Fungal endocarditis: analysis of 24 cases and review of the literature. Medicine (Baltimore) (1975) 2.61
Invasive infections due to a fish pathogen, Streptococcus iniae. S. iniae Study Group. N Engl J Med (1997) 2.60
Symptomatic relapse after oral vancomycin therapy of antibiotic-associated pseudomembranous colitis. Gastroenterology (1980) 2.60
Pharmacodynamics of fluconazole in a murine model of systemic candidiasis. Antimicrob Agents Chemother (1998) 2.59
Antimicrobial therapy of experimental intraabdominal sepsis. J Infect Dis (1975) 2.56
Impact of dosing intervals on activity of gentamicin and ticarcillin against Pseudomonas aeruginosa in granulocytopenic mice. J Infect Dis (1983) 2.56
Typing of Campylobacter pylori by bacterial DNA restriction endonuclease analysis and determination of plasmid profile. J Clin Microbiol (1990) 2.53
Genetic locus for streptolysin S production by group A streptococcus. Infect Immun (2000) 2.52
Anaerobic infections of the lung and pleural space. Am Rev Respir Dis (1974) 2.46
Effect of 2',3'-didehydro-3'-deoxythymidine in an in vitro hollow-fiber pharmacodynamic model system correlates with results of dose-ranging clinical studies. Antimicrob Agents Chemother (1994) 2.46
Influence of binding on the pharmacologic activity of antibiotics. Ann N Y Acad Sci (1973) 2.45
Reduced virulence of group A streptococcal Tn916 mutants that do not produce streptolysin S. Infect Immun (1998) 2.44
Genetic diversity of penicillin-binding protein 2B and 2X genes from Streptococcus pneumoniae in South Africa. Antimicrob Agents Chemother (1993) 2.44
Emergence of resistance to imipenem in Pseudomonas aeruginosa. Antimicrob Agents Chemother (1987) 2.44
Postantibiotic effect of imipenem on Pseudomonas aeruginosa. Antimicrob Agents Chemother (1984) 2.43
Pharmacodynamics of a new cephalosporin, PPI-0903 (TAK-599), active against methicillin-resistant Staphylococcus aureus in murine thigh and lung infection models: identification of an in vivo pharmacokinetic-pharmacodynamic target. Antimicrob Agents Chemother (2006) 2.42
In vivo pharmacodynamic activities of two glycylcyclines (GAR-936 and WAY 152,288) against various gram-positive and gram-negative bacteria. Antimicrob Agents Chemother (2000) 2.39
Prognostic indicators for AIDS and infectious disease death in HIV-infected injection drug users: plasma viral load and CD4+ cell count. JAMA (1998) 2.37
Preoperative oral antibiotics reduce septic complications of colon operations: results of prospective, randomized, double-blind clinical study. Ann Surg (1977) 2.36
A UK multicentre study of the antimicrobial susceptibility of bacterial pathogens causing urinary tract infection. J Infect (2003) 2.36
Genetic relatedness and superantigen expression in group A streptococcus serotype M1 isolates from patients with severe and nonsevere invasive diseases. Infect Immun (2000) 2.34
Experimental intra-abdominal abscesses in rats: quantitative bacteriology of infected animals. Infect Immun (1974) 2.33
Partial purification and characterization of a cytotoxin from Clostridium difficile. Rev Infect Dis (1980) 2.31